Life Sciences Industry Investors Luncheon

December 11th, 2012

Jean Colombel
VP Life Sciences Industry

DASSAULT SYSTEMES | IF WE ask the right questions we can change the world.

Agenda

1. Dassault Systèmes at a Glance
2. Patient-Centric Strategy
3. Medical Device
4. Pharma & Biotech
5. Q&A

Dassault Systèmes

Over €10bn Market Cap

Shareholders Composition



Over 10,000 Passionate People

- 100+ nationalities
- Serving 120+ countries
- One global R&D
- One architecture

>150,000 Enterprise Customers

- In 12 industries
- More than 1 million users on premises

3DEXPERIENCE Platform

- Open Architecture
- Open Components
- Open Communities

>3,500 Partners

- Research Institutes
- Education Partners
- Software and Technology Partners
- Sales & Services Partners

Our Purpose

"Dassault Systèmes provides Business & People with **3D**EXPERIENCE Universes to imagine sustainable innovations capable of harmonizing Product, Nature and Life"

Bernard CHARLES
President & Chief Executive Officer

Our Legacy: from 3D-Design to 3DEXPERIENCE

3D - Design



V3 | 1986

3D-DMU
Digital Mock-Up

V4 | 1994

3D-PLM
Product Lifecycle Management

V5 | 1999

3DEXPERIENCE

V6 | 2009

Agenda

1. Dassault Systèmes at a Glance
2. **Patient-Centric Strategy**
3. Medical Device
4. Pharma & Biotech
5. Q&A

Dassault Systèmes Patient-Centric Strategy

Agenda

1. Dassault Systèmes at a Glance
2. Patient-Centric Strategy
3. **Medical Device**
4. Pharma & Biotech
5. Q&A

Medical Devices Manufacturers Strategy



PLM and the Patient: Johnson & Johnson



webcast replay:
www.3DS.com/lifesciences

Expanding Market Reach

LUMENIS®
Enhancing Life. Advancing Technology.

DASSAULT SYSTEMES

Medical Device Company Lumenis Unifies Engineering and Business Processes with Dassault Systèmes' ENOVIA Version 6

Manage all Engineering Data While Ensuring Strict Quality Standards and Compliance to Regulations

KFAR SABA, Israel and PARIS (European Customer Forum) - November 23, 2011 - Dassault Systèmes (Euronext Paris: #13065, DSY.PA), a world leader in 3D and Product Lifecycle Management (PLM) solutions, announced today that Lumenis, the largest medical laser company in the world, has selected ENOVIA Version 6, after a meticulous evaluation process, to fully master the company's engineering information and business processes. ENOVIA and its Life Sciences Accelerators will be implemented to respond to Lumenis' aesthetic, ophthalmic, and surgical entities' needs across its entire organization.

ENOVIA Version 6 will provide Lumenis with an online collaborative framework to manage and control its planning processes in compliance with stringent quality standards and regulatory requirements across the company's full range of products and will include its entire supply chain. Lumenis will manage all engineering data in the different planning phases while integrating them with existing CAD systems. It will also facilitate the management of all product-related information (mechanical, [illegible] and software) on one single platform.

[illegible]NOVIA Version 6 PLM collaborative innovation platform, the [illegible]rators for Product Quality and Regulatory Affairs give [illegible]ring an end-to-end solution that spans the entire [illegible]iority of the quality systems processes [illegible]r contributors within the different [illegible]cess the information they [illegible]eveloped, crossing [illegible]ny manual

Agenda

1. Dassault Systèmes at a glance
2. Patient-Centric Strategy
3. Medical Device
4. **Pharma & Biotech**
5. Q&A

Addressing Pharma & Biotech Challenges

-50% New Drugs Output

+400% R&D $

- **Operational Excellence**
- **Extended Supply Chain**
- **New Markets**
- **Diversification**

1990 2000 2010 2020 .

3DExperiences for Pharma & Biotech



Multi-dimensional Complexity

Example for a Typical Large Pharma



Pierre Fabre Selected V6 for Global Efficiency



DASSAULT SYSTEMES

Pierre Fabre Laboratories Selects Dassault Systèmes' Version 6 Platform to Deploy Next-Generation PLM for Life Sciences

Leading Pharmaceutical and Dermo-cosmetics Group Replaces Most of its Existing Product Development Applications with Single PLM Platform;

Develop more cross-cutting activities, improve time to market and improve product traceability

PARIS (European Customer Forum), November 22, 2011 — Dassault Systèmes (Euronext Paris: #13065, DSY.PA), a world leader in 3D and Product Lifecycle Management (PLM) solutions, today announced that Pierre Fabre Laboratories has selected its ENOVIA Version 6 solution as its PLM platform. Delivering an up-to-the-minute, enterprise-wide vision of raw material and substance flows, as well as all associated regulatory documents and data, Dassault Systèmes' Version 6 platform will support the international expansion of Pierre Fabre Médicament (pharmaceuticals), Pierre Fabre Santé (family health) and Pierre Fabre Dermo-cosmétique (dermo-cosmetics).

Deployment will be phased in over the next four years. ENOVIA has already been successfully implemented to manage Pierre Fabre Laboratories' global dermo-cosmetics product portfolio, including formulas, raw materials, substances and country-specific products. As the backbone of this transformation, ENOVIA provides the enterprise-wide repository for full lifecycle product-related information, facilitating real-time collaboration decision-making among all departments – from purchasing and development to quality assurance, affiliates and partners.

family health and dermo-cosmetic products involves compliance with strict patient and consumer processes and decision-making. "Configured laboratories. PLM will

Pierre Fabre

Addressing Scientific New Frontier

BioIntelligence Consortium



DASSAULT SYSTEMES sobios

Solutions Partners

V6 Solution & Platform

Industry Partners

(Pharma,Agrochemistry , Cosmetics)

Public Research Institutes

Pierre Fabre Médicament · SANOFI · Bayer CropScience · IPSEN Innovation for patient care · SERVIER

Inria · genopole · Inserm

"The systemic modeling and simulation tools in this particularly innovative program will substantially improve the efficiency of biological research. BioIntelligence, and the BioPLM platform that will be developed by it, are entirely consistent with key objectives in European research." **EU Competition Commissioner Neelie Kroes.**

Conclusion

- On-Going Deep Transformation of Life Sciences Industry
- Strategic Commitment to this Industry
- Unique Positioning
- Strong Partnerships with Market Leaders